In February 2006, AzeRx was acquired by OrthoLogic (NASDAQ OLGC) - another Arizona firm being also SBIR involved in its own right. AzERx Inc., was created with the assistance of the Arizona Technology Enterprises, ASU's technology venturing company. AzeRx came out of Arizona State University to exploit the commercial applications of the principal's research findings that the imitator of the natural protein HSP20 causes relaxation in the same way as the natural protein. Researchers have developed a technique to aid coronary bypasses. They are focused to the development of a drug that promotes blood vessel relaxation. Severe spasm of blood vessels contributes to the failure of coronary bypass surgeries and to strokes following the rupture of an aneurysm in the brain.
